Tag Archives: Relatively

Relatively Unknown Secret Committees Have Been Influencing Insurers’ Drug Coverage Decisions For Decades

News outlets report on stories related to pharmaceutical pricing. Reuters: The Obscure Advisory Committees At The Heart Of The U.S. Drug Pricing Debate Expectations were high last year for three new migraine drugs hitting the market from Amgen Inc, Eli Lilly and Co and Teva Pharmaceutical Industries. Priced around $ 7,000 each, the drugmakers called… Read More »